Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer
Status:
Terminated
Trial end date:
2011-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Diagnostic procedures, such as 64Cu-labeled
diacetyl-bis[N4-methylthiosemicarbazone] (copper Cu 64-ATSM) PET/CT scans, may help doctors
predict how patients will respond to treatment.
PURPOSE: This phase II trial is studying how well copper Cu 64-ATSM PET/CT scans work in
predicting disease progression in patients undergoing standard of care treatment with
cisplatin and radiation therapy (external beam and brachytherapy) per National Comprehensive
Cancer Network (NCCN) guidelines for newly-diagnosed stage IB, stage II, stage III, or stage
IVA cervical cancer via the Federation of Gynecology and Obstetrics (FIGO) staging systems.